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Ovol1 encodes a zinc finger transcriptional repressor that is downstream of the LEF1/β-catenin complex, nuclear effectors of canonical Wnt
signaling. Previous gene knockout studies performed in a 129Sv×C57BL/6 mixed genetic background revealed that Ovol1-deficient mice survive
to adulthood but display multiple tissue defects. In this study, we describe a C57BL/6 strain-specific reduction in perinatal survival of Ovol1
mutant mice. The perinatal lethality is accompanied by kidney epithelial cysts of embryonic onset and delayed skin barrier acquisition. Genetic
analysis suggests a partial functional compensation by Ovol2 for the loss of Ovol1. The expression of Ovol2 was up-regulated in Ovol1-deficient
epidermis, and Ovol1 represses the activity of Ovol2 promoter in a DNA binding-dependent manner. Collectively, these studies uncover novel
functions of Ovol1 in mouse development and identify Ovol2 as a downstream target of Ovol1.
© 2006 Elsevier B.V. All rights reserved.Keywords: Ovol1; Ovol2; Perinatal lethality; Skin barrier; Cystic kidney; Transcriptional repression1. Introduction
Congenital abnormalities account for 11% of the perinatal
death of human infants, a serious health issue especially in
developing countries [1]. Understanding the genetic basis and
tissue involvement of such abnormalities will ultimately
facilitate the development of new and better treatment and
management strategies to reduce mortality.
The evolutionarily conserved ovo genes encode transcription
factors that either activate or repress gene expression and
include members that reside downstream of developmental
signaling pathways such as Wg/Wnt and BMP/TGF-β [2–4]. A
common theme that emerges from functional studies of this
gene family in various organisms is a requirement for the
development and differentiation of epithelial tissues and germ
cells [5–10]. While a single ovo gene exists in Drosophila and
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doi:10.1016/j.bbadis.2006.08.012Ovol1, Ovol2, and Ovol3 (also known as movo1, movo2, and
movo3, respectively [3]). Ovol1 is expressed in multiple
somatic epithelial tissues including skin and kidney, as well
as in the male germinal epithelium [5]. Gene knockout studies
revealed a functional requirement for Ovol1 in these expressing
tissues, as mutant mice deficient in Ovol1 showed ruffled hairs,
hyperproliferative epidermis, cystic kidneys, and defective
spermatogenesis [5,9,11]. Despite such pleotropic defects,
Ovol1 knockout mice maintained in a 129Sv×C57BL/6
(129×B6) mixed genetic background [5,9] survived to
adulthood with no apparent compromise in life-span. Ovol2
however, is essential for embryonic development, as Ovol2-
deficient mice die during mid-gestation [10]. Like Ovol1,
Ovol2 is also expressed in adult epithelial tissues such as skin
and kidney, and in the germinal epithelium of the testis [12].
It is not uncommon that genetic makeup affects the
phenotypic manifestation of a particular mutation, and in fact,
knockouts of several genes whose mutations affect epithelial
development and physiology, including EGFR, keratin 8, and
keratin 17, display phenotypic variations in different strain
backgrounds [13–18]. Since the initial characterizations of
Ovol1 mutant phenotypes were performed in a 129×B6 mixed
Table 1




Genotype distribution χ2 p value
Ovol1+/+ Ovol1+/− Ovol1−/−
129×B6 27 51 25 0.1 >0.9
B6 145 223 91 13.1 <0.005
CD1×B6 18 41 17 0.7 >0.5
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allele into a B6-enriched strain background in order to explore
additional functions of Ovol1 in mammalian development. Our
studies now reveal a novel function for Ovol1 in late embryonic
and perinatal survival. Specifically, we show that Ovol1 mutant
animals in the B6-enriched strain background die during late
embryonic stages and within the first 2 weeks after birth. This
compromised survival is accompanied by kidney cyst formation
and delayed skin barrier development in the embryos. We
present genetic data suggesting a functional compensation by
Ovol2 for the loss of Ovol1 in perinatal survival. Finally, we
provide molecular evidence demonstrating a direct negative
regulation of Ovol2 expression by Ovol1.
2. Materials and methods
2.1. Mouse breeding and genotyping
Ovol1+/− mice in a 129×B6 mixed genetic background were backcrossed
with B6 mice for 8–10 sequential generations to create “congenic” mice
containing the mutant allele (B6-Ovol1). B6-Ovol1+/− mice were then
intercrossed, and offspring (embryos or pups) were genotyped as previously
reported [5]. Ovol1+/−/Ovol2+/− double mutant mice were produced by crossing
Ovol1+/− and Ovol2+/− single mutants in a B6-enriched background. The double
heterozygotes were then intercrossed to generate compoundmutants for analysis.
2.2. Histology, barrier assays, and immunohistochemistry
Embryos were fixed in Bouin's fixative for 12–24 h at room temperature,
processed, and embedded in paraffin. Paraffin sections (5 μm) were prepared
and stained with hematoxylin and eosin, and analyzed for morphology. Dye
penetration assays were performed using freshly dissected embryos as described
[19]. Tails and/or paws were removed for genotyping prior to staining. For
immunohistochemistry, embryos were frozen in OCT, and sections (10 μm)
were prepared and fixed with 4% paraformaldehyde for 10 min, followed by
brief washes in PBS. Endogenous peroxidase was quenched by incubation in
freshly prepared 3%H2O2 solution for 15 min. After three 5-min washes in PBS,
sections were subject to immunohistochemical analysis using a polyclonal
antibody (1:50) against the full-length Ovol2 protein [20]. Images were acquired
using a Nikon Eclipse E600 microscope.
2.3. Northern blot analysis
Total RNA was extracted from skin of 2.5-month-old wild-type and B6-
Ovol1 mutant mice, and northern blot analysis was performed as described
[5] using a 320 bp PCR fragment containing sequences in exons 2 and 3 of
Ovol2 as a cDNA probe.
2.4. Electrophoretic mobility shift assay (EMSA)
EMSA assays were performed using different amounts (as indicated in
figure legends) of partially purified recombinant His6-Ovol1 and ∼20 fmol
(∼3×104 cpm) of gel-purified, 5′ 32P-end-labeled double-stranded oligonucleo-
tides. Typically, binding reactions were carried out in 20 μl volume containing
20 mM HEPES (pH 7.9), 75 mM KCl, 2.5 mM MgCl2, 2 mM DTT, 1 mM
EDTA, 12% glycerol and 1 μg of poly (dI–dC) for 30 min at room temperature.
In competition experiments, a 20- or 100-fold molar excess of unlabeled specific
or non-specific competitor was used. The protein–DNA complexes were
resolved on 6% non-denaturing polyacrylamide gels and visualized by
autoradiography.
2.5. Reporter assays
Assays were performed in 293T cells (a human kidney epithelial cell line) as
previously described [9]. A typical transfection mixture contained a total of0.5 μg of plasmids including 50 ng of pGL3-Ovol2 promoter construct or 10 ng
of its mutant derivative with varying amounts of vectors (as indicated in figure
legends) expressing Ovol1 [5] or VP16–Ovol1 [11], and 40 ng of a β-actin–β-
gal construct. pCB-6 (+) (empty vector containing the CMV promoter) was used
as stuffer DNA.3. Results
3.1. B6-Ovol1−/− mutants display perinatal lethality, cystic
kidneys with a developmental onset, and delayed skin barrier
acquisition
To explore novel functions of Ovol1 in mouse development,
we transferred the previously generated Ovol1 mutant allele
into a C57BL/6 (B6) strain background by 8–10 sequential
backcrosses. While in the 129×B6 mixed background homo-
zygous mutants were born at the expected Mendelian frequency
and survived to adulthood [5], intercrosses of Ovol1+/− mice
enriched with the B6 genome (B6-Ovol1+/−) yielded fewer than
expected Ovol1−/− pups when genotyped at postnatal day 14
(P14) (using χ2 test, p value is <0.005, indicating a <0.5%
probability of conforming to the Mendelian law, which predicts
a 1:2:1 ratio between +/+:+/−:−/−) (Table 1). This result
suggests that homozygous mutants died before P14 in this new
genetic background. To determine the timing of lethality,
offspring from such intercrosses were collected at earlier stages
and genotyped. Statistically significant deviations from the
Mendelian law were observed for newborns and for embryos
between the age of E15.5–E18.5, while approximate Mendelian
ratios were obtained at and before E14.5 (Table 2). The step-
wise decrease in the recovery of homozygous mutants from
E15.5 to P14 suggests that death occurred both during late
embryogenesis and in the first 2 postnatal weeks. The lethality
was completely rescued by a single outcross of the B6-Ovol1
mice with CD1 mice (Table 1), confirming that the requirement
for Ovol1 in embryonic/perinatal survival is specific to the B6
strain background.
The emergence of a novel lethality phenotype in a B6-
enriched background implicates the presence of genetic
modifier(s) of Ovol1 that functions differentially between B6
and 129 or CD1 strains. To address whether Ovol2 is such a
modifier, we genotyped the surviving and perinatal lethal
newborns for genetic markers flanking the Ovol2 locus
(D2Mit285 and D2Mit395), but found no linkage between the
Ovol2 locus and survival (data not shown). Therefore, it is
unlikely that a B6 allele of Ovol2 is responsible for the
Fig. 1. Kidney cysts and delayed barrier acquisition in B6-Ovol1 mutant mice.
(A) Wild-type (left) and mutant (right) kidneys at postnatal day 25. (B)
Histology of wild-type (left) and mutant (right) kidneys at E17.5. White
arrowheads indicate epithelial cysts in the mutant kidney, while no such cysts
were present in the wild-type control littermate. (C) Dye penetration assays of
wild-type (top) and mutant (bottom) embryo at the indicated ages. Scale bar:
20 μm in B.
Table 2
Genotype distribution of embryos and newborns from B6-Ovoll+/− intercrosses
Age of
offspring
Genotype distribution χ2 p value
Ovol1+/+ Ovol1+/− Ovol1−/−
<E14.5 13 26 14 0.06 >0.9
E15.5–E18.5 144 197 120 12.2 <0.005
P0 117 146 87 14.8 <0.005
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Ovol2 is providing a protective allele.
Late embryonic and perinatal death can be caused by
multiple defects such as developmental abnormalities in kidney
(for example [21,22]). Given our previous observation of a
mild adult cystic kidney phenotype in the 129×B6 mixed
background [5], we wondered whether B6-Ovol1 mutant mice
developed kidney abnormalities that are more severe or with an
earlier age onset. Indeed, many B6-Ovol1−/− mutants showed
severe unilateral or bilateral cystic kidneys that are apparent to
the eye as early as 3 weeks postnatally (Fig. 1A, right), whereas
in the original 129×B6 background such strong kidney
phenotypes were detected in much older mutant animals and
were always unilateral [23]. The penetrance of the defect is also
much higher than the previous background, as most surviving
B6-Ovol1−/− adults (>90%) displayed enlarged, fluid-filled
kidneys. At a histological level, epithelial cysts were apparent
as early as E17 in B6-Ovol1−/− embryos (Fig. 1B), whereas
previously histological kidney anomalies were only detected
postnatally [11]. No developmental defects were seen in
kidneys from B6-Ovol1+/− mice, and only one out of
approximately 40 adult heterozygotes showed a unilateral
cystic kidney.
Epidermal development during late embryogenesis gives rise
to a functional skin permeability barrier composed of cross-
linked proteins and lipids [24]. This barrier is essential for ex-
utero survival of both mice and humans, as mice born with a
defective barrier often die perinatally, whereas the onset of
barrier formation in human embryos correlates with the lower
age limit at which premature infants survive [24]. The lethality
of B6-Ovol1 mutant mice and the known function of Ovol1 in
developing epidermis [11] prompted us to use dye penetration
assays to examine whether B6-Ovol1 mutants were defective in
barrier development [19]. As expected, all wild-type embryos
showed precocious sites of dye extrusion at E16.5, and were
fully resistant to dye penetration by E17.5 (Fig. 1C, top). In
contrast, more than half of the B6-Ovol1−/− embryos (n=8)
showed no sign of barrier acquisition at E16.5, and all B6-
Ovol1−/− E17.5 embryos examined (n=5) showed only partial
dye extrusion (Fig. 1C, bottom). No apparent dye penetration
defects were observed for B6-Ovol1−/− embryos at E18.5 and
newborn (n=7), or for B6-Ovol1+/− embryos at all ages
examined (data not shown). These results indicate that B6-
Ovol1 homozygous mutant embryos were delayed in their
barrier acquisition by approximately 1 day. Collectively, our
findings reveal a previously unrecognized role for Ovol1 in
embryonic/perinatal survival, and in embryonic kidney and skin
barrier development.3.2. Ovo12 expression is up-regulated in Ovol1-deficient
epidermis and Ovol2 gene dosage affects the frequency of
perinatal lethality of Ovol1-deficient mice
Functional compensation has been frequently observed
between mammalian paralogs, and in such cases the expression
of one paralog may be up-regulated when the other is disrupted.
The incomplete penetrance of Ovol1−/− associated perinatal
lethality in the B6-enriched background led us to wonder
whether Ovol2 expression is up-regulated to compensate for the
loss of Ovol1. Northern blot analysis indeed detected
Fig. 2. Up-regulated Ovol2 expression in Ovol1-deficient epidermis. (A) Results of northern blot analysis on skin from a surviving 2.5-month-old Ovol1 −/− mouse
and a control littermate. The same blot was stripped and reprobed with GAPDH as a loading control. (B) Results of immunohistochemistry of wild-type (left) and
mutant (right) embryonic skin using a rabbit anti-Ovol2 antibody. Arrows indicate the presence of Ovol2 protein in suprabasal cells of the mutant. B, basal; S,
suprabasal. Scale bar: 10 μm in B.
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B6-Ovol1−/− mice than that from the wild-type littermates (Fig.
2A). We also compared the expression of Ovol2 protein in
wild-type and B6-Ovol1-deficient skin. In the wild-type
epidermis, nuclear Ovol2 protein was detected in the
proliferating basal layer, but not in differentiating suprabasal
layers that are known to express Ovol1 [5] (Fig. 2B). In
Ovol1−/− epidermis however, nuclear Ovol2 protein was
produced by not only basal but also suprabasal cells. Together,
these results demonstrate that the disruption of Ovol1 in skin
epidermis results in up-regulated expression of Ovol2,
particularly in the suprabasal layers.
We previously generated Ovol2-deficient mice and observed
embryonic death before E10.5 [10]. To examine whether Ovol2
provides a compensatory function for the loss of Ovol1, we first
generated Ovol1+/−Ovol2+/− compound heterozygotes, which
were fertile and displayed no overt phenotype (data not shown).
We then intercrossed these mice and genotyped their pups to
determine whether a reduction in the gene dosage of Ovol2
aggravated the postnatal lethality of Ovol1−/− mice. ConsistentTable 3
Genotype distribution of P14 pups from Ovol1+/−Ovol2+/− intercrosseswith the reported embryonic lethality caused by Ovol2mutation
[10], not a single double homozygous mutant was found at P14
among a total of 104 pups that were analyzed (data not shown).
Regardless of the Ovol2 genotype, the number ofOvol1−/− pups
that survived to this age was much lower than that of wild-type
littermates, confirming our conclusion above that Ovol1 is
required for optimum postnatal survival (Table 3). More
importantly, a significantly lower-than-expected frequency of
Ovol1−/−Ovol2+/− compound mutants (at a Mendelian ratio,
Ovol1−/−Ovol2+/− : Ovol1−/−Ovol2+/+ should be 2:1) was
observed (Table 3; χ2 =5.08, p value is <0.025, indicating a
<2.5% probability of conforming to the Mendelian law). To
examine whether the loss of both Ovol genes may lead to an
earlier embryonic lethality than that are caused by the loss of
Ovol2 alone, we also analyzed embryos from such intercrosses
at E8.5. An expected frequency of occurrence was observed for
Ovol1−/−Ovol2−/− embryos (5.75 was expected out of 92
embryos analyzed; 5 was observed), and these double mutants
are morphologically identical to Ovol2−/− single mutants (data
not shown). Collectively, these results indicate that the Ovol2
93A. Teng et al. / Biochimica et Biophysica Acta 1772 (2007) 89–95gene dosage affects the manifestation of the perinatal lethal
phenotype of Ovol1-deficient animals, but argue against the
notion that Ovol1 plays a redundant function for Ovol2 in early
embryonic survival.
3.3. Molecular evidence that Ovol2 is a downstream target of
Ovol1 transcriptional repression
We have previously reported that Ovol1 is a transcriptional
repressor [9,11]. The up-regulation of Ovol2 expression in
Ovol1−/− suprabasal epidermal cells prompted us to test
whether Ovol2 is a target of Ovol1 repression. We examined
the sequence of an Ovol2 promoter fragment (1816 base
pairs) that is able to direct active transcription in 293T cells
(see below) for putative Ovol1 binding sites. Two CCGTTA
elements, known to be the recognition consensus for Ovol1
[11], were found. Oligonucleotides Ovol2u and Ovol2d
containing the upstream and downstream elements, respec-
tively, were tested for Ovol1 binding using EMSA assays.
Ovol1 bound to both Ovol2u and Ovol2d, and the sequence-
specificity of the interaction was confirmed by competition by
an excess amount of unlabeled specific (lanes 7, 8) but not
non-specific (lanes 9, 10) oligonucleotides (Fig. 3A).
Furthermore, the identity of the Ovol1–DNA complex was
confirmed by the observation of a band supershift when anti-Fig. 3. Ovol1 binds to sequences in the Ovol2 promoter and represses its activity in
Ovol2d (right) oligonucleotides. Lanes 1, 5, 12: no protein added. Lanes 2, 6, 13
Ovol1. Lanes 4 and 15: with 0.5 μg recombinant Ovol1. Lanes 7–11: same as lane
unlabeled specific (lanes 7, 8) or non-specific (lanes 9, 10) oligonucleotides, or in th
Ovol1–DNA and Ovol1–DNA–antibody complexes, respectively. Arrowheads indi
Ovol2 promoter by Ovol1 (B) and VP16–Ovol1 (C), respectively. The triangle in B in
expression vector. P, wild-type promoter; MutP, mutant promoter in which the Ovol1
in a single experiment, and results are representative of several independent experimen
actin promoter driving lacZ as an internal control.Ovol1 antibody was added to the binding reaction (Fig. 3A,
lane 11). Therefore, Ovol2 promoter contains bona fide Ovol1
binding sites.
We next used reporter assays to examine the effect of Ovol1
on Ovol2 promoter activity. To do this, we cloned the Ovol2
promoter fragment upstream of a luciferase reporter gene. Co-
transfection with an Ovol1 expression vector led to a dosage-
dependent repression of the activity of this promoter (Fig. 3B).
Since repression can sometimes result as an artifact from high
levels of protein expression, we turned to test whether VP16–
Ovol1, a fusion protein that was shown to activate known
Ovol1 target genes [9,11], can activate the Ovol2 promoter.
This fusion protein indeed activated the Ovol2 promoter in a
dosage-dependent manner (Fig. 3C), while VP16 alone had no
effect (data not shown). To address whether the observed
regulation depends on Ovo11 binding to the promoter, we
repeated the experiments, this time using a mutant promoter
where both Ovol1 binding sites were removed (by replacing
the CCGTTA sequence with a hexamer to which Ovol1 does
not bind; [11]). A significant reduction in the degree of
activation by VP16–Ovol1 was observed (Fig. 3C), indicating
that the maximum effect of Ovol1 on Ovol2 promoter activity
requires Ovol1 binding to these sites. Collectively, these results
demonstrate that Ovol1 represses Ovol2 transcription by
binding to its promoter.reporter assays. (A) EMSA assays were carried out with the Ovol2u (left) and
: with 0.2 μg recombinant Ovol1. Lanes 3 and 14: with 0.3 μg recombinant
6 but in the presence of a 20- (lanes 7, 9) or 100-fold (lanes 8, 10) excess of
e presence of an anti-Ovol1 antibody (lane 11). Black ovals and ⁎ indicate the
cate the position of the free probes. (B–C) Repression (B) and activation (C) of
dicates increasing concentrations (0, 0.01 μg, 0.02 μg, and 0.05 μg) of the Ovol1
binding sites are disrupted. Each bar represents the average of triplicate samples
ts. Luciferase activities were normalized for transfection efficiency by using a β-
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Our studies have identified a novel function of Ovol1 in late
embryonic/postnatal survival. Furthermore, these results dem-
onstrate that the manifestation of this function is dependent on
the strain background where the Ovol1 mutant alleles reside.
There has been an increasing recognition that many Mendelian
traits that result in birth defects or adult diseases in mice or
human vary in their phenotypic manifestations due to the
presence of genetic modifiers [25]. Our work now adds Ovol1
to the list of genes, including EGFR, keratin 8, and keratin 17,
the function of which is influenced by strain-specific modifier
(s) [13–18]. Future work to identify such modifier(s) offers
exciting opportunities to unravel novel genetic players or
pathways that govern developmental processes in which Ovol1
is required.
What is the underlying basis of perinatal lethality of Ovol1
knockout mice? While we do not have a definitive answer to
this question, we observed defects that are known to associate
with perinatal lethality. All mutant embryos examined were able
to extrude dye by birth despite a developmental delay in barrier
acquisition, making it unlikely that a barrier defect is the
underlying cause of lethality. This said, we note that the
frequency of a delayed barrier (approximately half) in Ovol1−/−
embryos is intriguingly similar to that of postnatal lethality of
Ovol1−/− pups. Furthermore, half of the Ovol1−/− pups contain
cornified envelopes, important constituents of the actual barrier,
that show lower resistance to mechanical stress (data not
shown). Therefore, we cannot fully exclude the possibility that a
compromised barrier under environmental stresses contributes
to a certain extent to the reduced ex utero survival of Ovol1
mutant animals. Kidney defect is likely an important contrib-
uting factor to lethality. The developmental onset of kidney
cysts in B6-Ovol1−/− animals is reminiscent of that observed in
mice mutant for PKD1, a major target of cystic kidney diseases
in humans [22]. PKD1-deficient mice die perinatally, presenting
an interesting parallel with the B6-Ovol1−/− mice. Most known
proteins whose mutations cause cystic renal diseases are
localized to the primary cilium of renal tubular epithelial cells
[26,27]. Our finding that deletion of Ovol1, a regulatory instead
of structural protein, also causes kidney cysts is a first. Our B6-
Ovol1−/− mice should now provide a useful animal model to
study the regulatory mechanisms underlying kidney develop-
ment and the molecular basis of human cystic kidney diseases.
We used genetic approaches to address the possibility that
Ovol2 provides a compensatory function for the loss of
Ovol1. We found that mice with only the two Ovol1 alleles
disrupted (Ovol1−/−Ovol2+/+) survived better than those with
both Ovol1 alleles as well as a copy of the Ovol2 allele
disrupted (Ovol1−/−Ovol2+/−). Taking this result together with
our observation of increased Ovol2 expression in an Ovol1-
deficient background, we surmise that the elevated expression
of Ovol2 compensates for the loss of Ovol1, and that this
compensation is insufficient with only one wild-type copy of
Ovol2. Based on this finding, we predict that a complete
penetrance of perinatal lethality and/or additional phenotypes
might surface when both alleles of Ovol2 are deleted in theOvol1-deficient background. Since Ovol2 homozygous deletion
causes embryonic lethality prior to the stage when Ovol1
function is required, a conditional deletion of Ovol2 needs to be
performed to address this notion.
The existing model suggests that Ovol1 functions to regulate
the transition of epithelial progenitor cells from proliferation to
terminal differentiation possibly by regulating the expression of
downstream target genes including c-Myc and Id2 [9,11]. Our in
vivo and in vitro studies now add Ovol2 to the list of Ovol1
downstream targets. Under physiological conditions, Ovol2 is
expressed in the proliferating basal but not differentiating
suprabasal cells of the epidermis. This expression pattern is
reminiscent of c-Myc and Id2, known positive regulators of
proliferation and negative regulators of differentiation. Does
Ovol2 function similarly like c-Myc or Id2 to positively
regulate proliferation and negatively regulate terminal differ-
entiation? While this may be the case in normal epidermis, the
observed compensation by Ovol2 for the loss of Ovol1 suggests
that the situation under diseased conditions (e.g., when Ovol1 is
lost) is more complex. Clearly, additional studies are warranted
to understand the role of Ovol2 in epidermal proliferation and
differentiation under physiological and pathological conditions.
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